Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
P414192-5mg | 5mg | In stock | $286.90 | |
P414192-10mg | 10mg | In stock | $566.90 | |
P414192-25mg | 25mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $866.90 | |
P414192-50mg | 50mg | In stock | $1,333.90 | |
P414192-100mg | 100mg | In stock | $2,133.90 |
JAK2 Selective Inhibitors
Synonyms | Brepocitinib|PF-06700841 free base|PF-06700841|1883299-62-4|Brepocitinib [USAN]|3X8387Q25N|Brepocitinib (USAN)|[(1S)-2,2-difluorocyclopropyl]-[(1S,5R)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone|[(1S)-2,2- |
---|---|
Specifications & Purity | 95% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Tyrosine-protein kinase JAK1 inhibitor |
ALogP | 1.608 |
---|---|
HBD Count | 1 |
Rotatable Bond | 4 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 488202657 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488202657 |
IUPAC Name | [(1S)-2,2-difluorocyclopropyl]-[(1R,5S)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone |
INCHI | InChI=1S/C18H21F2N7O/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24)/t12-,13+,14-/m0/s1 |
InChi Key | BUWBRTXGQRBBHG-MJBXVCDLSA-N |
Canonical SMILES | CN1C=C(C=N1)NC2=NC=CC(=N2)N3CC4CCC(C3)N4C(=O)C5CC5(F)F |
Isomeric SMILES | CN1C=C(C=N1)NC2=NC=CC(=N2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F |
Alternate CAS | 2140301-96-6 |
PubChem CID | 118878093 |
Molecular Weight | 389.4 |
PubChem CID | 118878093 |
---|---|
CAS Registry No. | 1883299-62-4 |
RCSB PDB Ligand | G4J |
PubChem SID | 488202657 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
C2320305 | Certificate of Analysis | Dec 20, 2022 | P414192 |
C2320307 | Certificate of Analysis | Dec 20, 2022 | P414192 |
C2320327 | Certificate of Analysis | Dec 20, 2022 | P414192 |
C2320345 | Certificate of Analysis | Dec 20, 2022 | P414192 |
C2320346 | Certificate of Analysis | Dec 20, 2022 | P414192 |
C2320349 | Certificate of Analysis | Dec 20, 2022 | P414192 |
C2320353 | Certificate of Analysis | Dec 20, 2022 | P414192 |
C2320354 | Certificate of Analysis | Dec 20, 2022 | P414192 |
C2320358 | Certificate of Analysis | Dec 20, 2022 | P414192 |
Solubility | Solubility (25°C) In vitro DMSO: 78 mg/mL (200.3 mM); Ethanol: 78 mg/mL (200.3 mM); Water: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 78 |
DMSO(mM) Max Solubility | 200.308166409861 |
Water(mg / mL) Max Solubility | <1 |
Starting at $241.90
1. Fensome A, Ambler CM, Arnold E, Banker ME, Brown MF, Chrencik J, Clark JD, Dowty ME, Efremov IV, Flick A et al.. (2018) Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).. J Med Chem, 61 (19): (8597-8612). [PMID:30113844] |